John R Falck Selected Research

Angiotensin II

1/2022	Macrophage 12(S)-HETE Enhances Angiotensin II-Induced Contraction by a BLT2 (Leukotriene B4 Type-2 Receptor) and TP (Thromboxane Receptor)-Mediated Mechanism in Murine Arteries.
8/2021	Effects of Epoxyeicosatrienoic Acid-Enhancing Therapy on the Course of Congestive Heart Failure in Angiotensin II-Dependent Rat Hypertension: From mRNA Analysis towards Functional In Vivo Evaluation.
1/2019	Epoxyeicosatrienoic Acid-Based Therapy Attenuates the Progression of Postischemic Heart Failure in Normotensive Sprague-Dawley but Not in Hypertensive Ren-2 Transgenic Rats.
10/2018	20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats.
1/2018	Two pharmacological epoxyeicosatrienoic acid-enhancing therapies are effectively antihypertensive and reduce the severity of ischemic arrhythmias in rats with angiotensin II-dependent hypertension.
10/2016	Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats.
10/2014	Epoxyeicosatrienoic acid analogue lowers blood pressure through vasodilation and sodium channel inhibition.
1/2014	Epoxyeicosatrienoic acid analog attenuates angiotensin II hypertension and kidney injury.
11/2010	CYP4A2-induced hypertension is 20-hydroxyeicosatetraenoic acid- and angiotensin II-dependent.
10/2010	Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John R Falck Research Topics

Disease

53	Hypertension (High Blood Pressure) 01/2023 - 07/2004
24	Inflammation (Inflammations) 03/2021 - 10/2005
23	Ischemia 01/2024 - 10/2004
16	Neoplasms (Cancer) 01/2023 - 12/2004
15	Hypoxia (Hypoxemia) 01/2024 - 08/2002
15	Infarction (Infarctions) 11/2018 - 10/2004
13	Reperfusion Injury 07/2020 - 10/2004
12	Insulin Resistance 05/2024 - 12/2009
12	Obesity 01/2021 - 03/2008
11	Myocardial Infarction 01/2023 - 10/2004
10	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 05/2005
9	Septic Shock (Toxic Shock Syndrome) 01/2023 - 01/2012
9	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2018 - 01/2009
8	Hypotension (Low Blood Pressure) 01/2022 - 01/2012
8	Fibrosis (Cirrhosis) 01/2019 - 01/2013
6	Proteinuria 01/2019 - 10/2009
5	Tachycardia (Tachyarrhythmias) 01/2022 - 04/2013
5	Heart Failure 09/2021 - 01/2015
5	Hyperemia 01/2017 - 08/2005
4	Vascular Remodeling 01/2023 - 04/2006
4	Cardiomegaly (Heart Hypertrophy) 09/2021 - 02/2010
4	Breast Neoplasms (Breast Cancer) 10/2017 - 05/2011
4	Stroke (Strokes) 05/2017 - 12/2007
4	Body Weight (Weight, Body) 01/2012 - 12/2006
3	Prostatic Neoplasms (Prostate Cancer) 01/2023 - 12/2004
3	Hyperglycemia 01/2021 - 06/2006
3	Albuminuria 01/2019 - 01/2014
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2018 - 09/2011
3	Carcinogenesis 01/2018 - 06/2007
3	Renovascular Hypertension (Goldblatt Syndrome) 01/2016 - 12/2009
3	Hypertrophy 03/2015 - 02/2010
3	Vascular Ring 05/2011 - 08/2004
3	Myocardial Ischemia (Ischemic Heart Diseases) 01/2008 - 10/2004
2	Hyperlipidemias (Hyperlipidemia) 05/2024 - 01/2014
2	Cerebral Hemorrhage 01/2021 - 01/2019
2	Cardiac Arrhythmias (Arrythmia) 11/2019 - 01/2013

Drug/Important Bio-Agent (IBA)

72	20-hydroxy-5,8,11,14-eicosatetraenoic acidIBA 01/2023 - 08/2002
62	AcidsIBA 05/2024 - 10/2004
45	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 05/2024 - 07/2004
22	Arachidonic Acid (Vitamin F)IBA 01/2021 - 07/2004
16	EicosanoidsIBA 01/2023 - 01/2007
13	EnzymesIBA 05/2024 - 04/2005
12	AndrogensIBA 01/2023 - 12/2004
12	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2005
12	Epoxide HydrolasesIBA 01/2019 - 04/2005
12	Cytochrome P-450 CYP4A (Alkane 1 Monooxygenase)IBA 01/2019 - 07/2004
11	Hydroxyeicosatetraenoic Acids (HETE)IBA 01/2023 - 04/2005
11	Angiotensin IIIBA 01/2022 - 02/2010
11	14,15-epoxy-5,8,11-eicosatrienoic acidIBA 10/2019 - 10/2005
11	Mixed Function Oxygenases (Monooxygenases)IBA 11/2018 - 10/2004
9	HET0016IBA 01/2019 - 02/2005
9	SodiumIBA 12/2017 - 06/2006
9	SaltsIBA 01/2016 - 06/2006
8	Vasoconstrictor AgentsIBA 12/2019 - 02/2004
7	Glycine (Aminoacetic Acid)FDA LinkGeneric 01/2022 - 03/2009
7	LipopolysaccharidesIBA 01/2022 - 03/2009
7	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2020 - 08/2002
6	LipidsIBA 05/2024 - 01/2012
6	Messenger RNA (mRNA)IBA 08/2021 - 12/2005
6	CytochromesIBA 01/2021 - 10/2004
6	cytochrome P-450 CYP2C subfamilyIBA 11/2018 - 06/2007
5	Insulin (Novolin)FDA Link 05/2024 - 11/2018
5	N-(20-hydroxyeicosa-5,14-dienoyl)glycineIBA 01/2022 - 04/2013
5	CytokinesIBA 12/2019 - 01/2012
5	ReninIBA 10/2018 - 12/2009
5	Antihypertensive Agents (Antihypertensives)IBA 01/2018 - 01/2014
5	AngiotensinsIBA 10/2017 - 01/2010
5	N- methylsulfonyl- 6- (2- propargyloxyphenyl)hexanamideIBA 01/2014 - 12/2004
5	Vasodilator Agents (Vasodilators)IBA 07/2013 - 07/2005
5	11,12-epoxy-5,8,14-eicosatrienoic acidIBA 06/2010 - 12/2005
4	Glucose (Dextrose)FDA LinkGeneric 05/2024 - 10/2017
4	EET-BIBA 01/2019 - 11/2013
4	DDMSIBA 01/2016 - 10/2004
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2016 - 09/2011
4	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2014 - 07/2005
4	ProstaglandinsIBA 07/2013 - 07/2005
4	Adenosine Triphosphate (ATP)IBA 03/2007 - 08/2002
3	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2022 - 05/2017
3	LigandsIBA 01/2021 - 06/2007
3	EndotoxinsIBA 12/2019 - 01/2012
3	Oxygen (Dioxygen)IBA 12/2019 - 12/2009
3	Nitric Oxide Synthase (NO Synthase)IBA 12/2019 - 08/2002
3	Phenylephrine (Neo-Synephrine)FDA LinkGeneric 10/2019 - 08/2004
3	CreatinineIBA 01/2019 - 10/2009
3	Heme Oxygenase (Decyclizing) (Heme Oxygenase)IBA 08/2017 - 12/2008
3	Cytochrome P-450 CYP2J2 (CYP2J2)IBA 01/2017 - 10/2010
3	salicylhydroxamic acid (SHAM)IBA 01/2017 - 03/2010
3	OxylipinsIBA 01/2017 - 01/2017
3	AdiponectinIBA 01/2015 - 12/2008
3	formamidine (formamidinium)IBA 03/2009 - 11/2005
2	Cisplatin (Platino)FDA LinkGeneric 03/2021 - 08/2013
2	Therapeutic UsesIBA 03/2021 - 12/2010
2	NitrogenIBA 12/2019 - 01/2012
2	BradykininIBA 12/2019 - 12/2011
2	erucylphosphocholineIBA 01/2019 - 03/2014
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2019 - 02/2008

Therapy/Procedure

5	Therapeutics 08/2021 - 03/2017
3	Surgical Instruments (Clip) 10/2015 - 12/2009
2	Controlled Hypotension 01/2022 - 01/2012
2	Lasers (Laser) 01/2022 - 05/2011